Meet
Sung Hee Choe

Sung Hee Choe oversees Avalere’s 360 research series, which provides clients with analysis, insights, and educational resources related to developments and emerging trends in healthcare.

In this role, she builds on her extensive experience advising clients on healthcare policy, public and private payer trends, comparative effectiveness research, and patient engagement.

Prior to joining Avalere, Sung Hee spent 10 years in the financial services industry. Most recently, she served as vice president at Bank of New York Asset Management and at First Republic Investment Management, where she analyzed healthcare sector equities to identify investment opportunities.

Sung Hee has a BA in English and economics from Mount Holyoke College. She is a CFA® charterholder.

Authored Content


Transformative medicines, like gene and cell therapies, are beginning to be approved in the US, and more are expected to come.

Today, the Trump Administration released its budget for fiscal year 2019 (FY 2019).

2018 will bring change from all parts of the healthcare system.

Avalere experts expand on significant priorities for 2018.

Elevate your perspective to adapt to the 2018 healthcare environment. Watch a preview of moderator Caroline Pearson set the stage for our 2018 Healthcare Industry Outlook.

Avalere's President and Founder, Dan Mendelson, recently wrote a column about the new strategies that device manufacturers should take in this era of healthcare.

New research from Avalere finds that most health plans are covering at least one of the two biosimilar products currently on the market.

The 21st Century Cures Act presents medical product manufacturers, patient groups, and advocacy organizations with a unique opportunity to plan for upcoming policy changes that are aimed at accelerating the pace of development and approval of new therapies.

Avalere experts say use of outcomes-based contracts could further goals to improve patient outcomes and manage drug costs

Avalere experts discuss the top priorities to focus on as you navigate the new landscape.

This year will be the start of major environmental changes for the healthcare industry following a shift in the balance of power in Washington, DC, and the states.

This summer, the Institute for Clinical and Economic Review (ICER) opened a national call for suggestions on how to improve its value assessment framework. In response, ICER received over 50 comments. On October 4, ICER made 46 of those comment letters public.

The plans are waiting to see how frameworks will evolve and if physicians embrace them before relying on them to decide which prescription drugs to cover.

Earlier today, the Centers for Medicare and Medicaid Services (CMS) released participation information for its new Oncology Care Model (OCM) slated to begin July 1.

Hepatitis C and Oncology Are Top Therapeutic Area Targets

In 2016, two key themes underlie much of the shift in the healthcare landscape: cost and value. Each of these elements is critical to all sectors of the healthcare system as we attempt to reduce costs and deliver value.

Get a sense of what to anticipate in the 2016 healthcare landscape in our annual 2016 Industry Outlook: Reducing Cost and Demonstrating Value.

In 2016, 2 key themes underlie much of the shift in the healthcare landscape: cost and value. Each of these elements is critical as we attempt to reduce costs by improving value across the healthcare system. Caroline Pearson, Senior Vice President, Strategy and Policy, gives a preview of what to expect.

In recognition of National Healthcare Quality Week, we sat down with Avalere expert Nelly Ganesan to discuss upcoming trends and developments for physician quality measurement.


In this year's Outlook, Avalere experts analyze which key events will impact your industry most, and when to start to prepare.

In this podcast, Matt Eyles, Executive Vice President of Health Plans and Providers, gives a short preview of his upcoming MHPA presentation, Medicaid Premium Assistance Programs: Opportunities and Challenges for States and Plans.

Comparative effectiveness research (CER) has the potential to inform many decisions. While a common threshold for determining whether a CER finding should be disseminated to the public is its methodological quality, a study with high methodological quality is not necessarily one that patients and providers will find usable for their decision making.